|
|
Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 388)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Fluorouracil | approved | Phase 3, Phase 2, Phase 1 | 1856 | 51-21-8 | 3385 | 1-fluoro-1h-pyrimidine-2,4-dione 1004-03-1 1upf 2,4-Dihydroxy-5-fluoropyrimidine 2,4-Dioxo-5-fluoropryimidine 2,4-Dioxo-5-fluoropyrimidine 47576_FLUKA 4921-97-5 5 FU Lederle 5 FU medac 5 Fluorouracil 5 Fluorouracil biosyn 5 HU Hexal 5-FU 5-FU (TN) 5-FU Lederle 5-FU medac 5-Faracil 5-Fluor-2,4(1H,3H)-pyrimidindion 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech] 5-Fluor-2,4-dihydroxypyrimidin 5-Fluor-2,4-dihydroxypyrimidin [Czech] 5-Fluor-2,4-pyrimidindiol 5-Fluor-2,4-pyrimidindiol [Czech] 5-Fluoracil 5-Fluoracil [German] 5-Fluoracyl 5-Fluoro-2,4(1H,3H)-pyrimidinedione 5-Fluoro-2,4-pyrimidinedione 5-Fluoropyrimidin-2,4-diol 5-Fluoropyrimidine-2,4-dione 5-Fluorouracil 5-Fluorouracil-biosyn 5-Fluoruracil 5-Fluoruracil [German] 5-Fluracil 5-Ftouracyl 5-HU Hexal 5-fluoro uracil 5-fluoro-1H-pyrimidine-2,4-dione 5-fluoropyrimidine-2,4(1H,3H)-dione 5-fluorouracil 51-21-8 5FU 79108-01-3 AC-11201 AC1L1FTE AC1Q4N2X AI3-25297 AKOS000119162 AKOS003237897 AccuSite Actino-Hermal Adrucil Adrucil (TN) Allergan Brand of Fluorouracil Arumel BB_NC-0576 BSPBio_002048 C07649 C4H3FN2O2 CCRIS 2582 CHEBI:46345 CHEMBL185 CID3385 CPD0-1327 CPD000038082 CSP Brand of Fluorouracil Carac Carac (TN) Carzonal Cinco FU Cytosafe D005472 D00584 DB00544 Dakota Brand of Fluorouracil Dakota, Fluorouracile Dermatech Brand of Fluorouracil Dermik Brand of Fluorouracil DivK1c_000054 EINECS 200-085-6 EU-0100536 Effluderm Effluderm (free base) Efudex Efudix Efurix F 6627 F0151 F6627_SIGMA F8423_SIGMA FT-0082524 FU Ferrer Brand of Fluorouracil Fiverocil Fluoro Uracil Fluoro Uracile ICN Fluoro-Uracile ICN Fluoro-uracile Fluoro-uracilo Fluoroblastin Fluoroplex Fluoroplex (TN) Fluorouracil Fluorouracil (JP15/USP/INN) Fluorouracil GRY Fluorouracil Mononitrate Fluorouracil Monopotassium Salt Fluorouracil Monosodium Salt Fluorouracil Potassium Salt Fluorouracil Teva Brand Fluorouracil [USAN:INN:BAN:JAN] | Fluorouracil-GRY Fluorouracile Fluorouracile Dakota Fluorouracile [DCIT] Fluorouracilo Fluorouracilo Ferrer Far Fluorouracilo [INN-Spanish] Fluorouracilum Fluorouracilum [INN-Latin] Fluoruracil Fluouracil Flurablastin Fluracedyl Fluracil Fluracilum Fluri Fluril Fluro Uracil Fluroblastin Flurodex Flurouracil Flurox Ftoruracil Gry Brand of Fluorouracil HMS1920O18 HMS2090I04 HMS2091F19 HMS500C16 HSDB 3228 Haemato Brand of Fluorouracil Haemato fu Haemato-fu Hexal Brand of Fluorouracil I07-0022 ICN Brand of Fluorouracil IDI1_000054 IN1335 KBio1_000054 KBio2_001321 KBio2_003889 KBio2_006457 KBio3_001268 KBioGR_001253 KBioSS_001321 Kecimeton LS-153 Lopac-F-6627 Lopac0_000536 MLS000069498 MLS002415705 MolPort-000-156-102 MolPort-003-990-447 MolPort-004-758-143 MolPort-004-758-144 MolPort-005-861-486 NCGC00015442-01 NCGC00015442-03 NCGC00015442-10 NCGC00091349-01 NCGC00091349-02 NCGC00091349-03 NCGC00091349-04 NCGC00091349-05 NCGC00091349-07 NCGC00091349-08 NCI60_001652 NINDS_000054 NSC 19893 NSC-19893 NSC19893 Neocorp Brand of Fluorouracil Neofluor Onkofluor Onkoworks Brand of Fluorouracil Phthoruracil Phtoruracil Queroplex Ribofluor Riemser Brand of Fluorouracil Ro 2-9757 Ro-2-9757 Roche Brand of Fluorouracil S1209_Selleck SAM002264615 SMR000038082 SPBio_000291 SPECTRUM1500305 STK297802 Spectrum2_000076 Spectrum3_000434 Spectrum4_000557 Spectrum5_000718 Spectrum_000841 T5233394 TL8006093 Teva Brand of Fluorouracil Timazin U 8953 U-8953 UNII-U3P01618RT UPCMLD-DP130 UPCMLD-DP130:001 URF Ulup WLN: T6MVMVJ EF ZINC00897110 biosyn Brand of Fluorouracil fluorouracil inhibits thymilidate synthetase medac Brand of Fluorouracil nchembio.90-comp3 nchembio809-comp6 ribosepharm Brand of Fluorouracil tetratogen | |
| | 2 | | Oxaliplatin | approved, investigational | Phase 3, Phase 2, Phase 1 | 1460 | 61825-94-3 | 5310940, 9887054, 6857599, 9887054, 43805 | CHEMBL1201055 CID9887054 D01790 DACPLAT Diaminocyclohexane Oxalatoplatinum Eloxatin Eloxatin (TN) Elplat Foloxatine L-OHP Oxalatoplatin | Oxalatoplatinum Oxaliplatin (JAN/USAN/INN) Oxaliplatin [Usan:Inn:Ban] Oxaliplatino [Spanish] Oxaliplatinum [Latin] Oxaloplatine [French] Oxaloplatino [Spanish] Transplatin oxaliplatin oxaliplatine oxaliplatino oxaliplatinum | |
| | 3 | | Carboplatin | approved | Phase 2, Phase 3, Phase 1 | 2050 | 41575-94-4 | 10339178, 498142, 38904 | (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum /h1-3H2,(H,7,8)(H,9,10) /q 1,1-Cyclobutanedicarboxylate diammine platinum (II) 1,1-Cyclobutanedicarboxylate diammine platinum(II) 2*-1 2*1H2 41575-94-4 70903-55-8 AC-1457 AC1L8I6U Ambap41575-94-4 BSPBio_003145 C 2538 C2043 C2538_SIGMA C6H10N2O4Pt CBDCA CCRIS 3404 CHEBI:31355 CHEMBL1351 CHEMBL288376 CID10339178 CID2567 CID38904 CID426756 CID498142 CID5352133 CID6398587 CID6603770 Carbopaltin Carboplatin Carboplatin (JAN/USP/INN) Carboplatin (USAN) Carboplatin [USAN:INN:BAN:JAN] Carboplatine Carboplatine [French] Carboplatino Carboplatino [Spanish] Carboplatinum Carboplatinum [Latin] Cbdca Cyclobutane-1,1-dicarboxylate D01363 DB00958 Diammine(1,1-cyclobutanedicarboxylato)platinum (II) Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum Diammine-1,1-cyclobutane dicarboxylate platinum II DivK1c_000892 EINECS 255-446-0 EU-0100230 Ercar HMS1921J16 HMS2090M05 HMS2092B22 HMS502M14 HSDB 6957 I14-2390 IDI1_000892 IUPAC: Azane InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6 | JM 8 JM-8 KBio1_000892 KBio2_002009 KBio2_004577 KBio2_007145 KBio3_002645 KBioGR_000713 KBioSS_002009 LS-117689 Lopac-C-2538 Lopac0_000230 MolPort-003-665-501 MolPort-003-845-609 NCGC00015223-01 NCGC00093695-01 NCGC00094961-01 NCGC00094961-02 NCGC00094961-03 NCGC00162099-01 NCGC00162099-02 NCGC00167800-01 NCGC00178242-01 NINDS_000892 NSC 201345 NSC 241240 NSC-241240 NSC201345 NSC241240 Paraplatin Paraplatin (TN) Paraplatin, Carboplatin Paraplatin-AQ Platinum(+2) Cation Platinum(II), (1, 1-cyclobutanedicar Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2) Platinum, {diammine[1,1-cyclobut S1215_Selleck SPBio_000716 SPECTRUM1502106 Spectrum2_000898 Spectrum3_001503 Spectrum4_000337 Spectrum5_001094 Spectrum_001529 UNII-BG3F62OND5 azanide carboplatin cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II) cis-Diammine(1,1-cyclobutanedicarboxylato) platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diammine(cyclobutanedicarboxylato)platinum II cyclobutane-1,1-dicarboxylic acid diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum nchembio.573-comp10 nchembio773-comp2 nchembio873-comp3 platinum(2+) |
| | 4 | | Bevacizumab | approved, investigational | Phase 3, Phase 2, Phase 1 | 2020 | 216974-75-3 | | 216974-75-3 Avastin Avastin (TN) Bevacizumab Bevacizumab (genetical recombination) | Bevacizumab (genetical recombination) (JAN) D06409 R-435 anti-VEGF monoclonal antibody antiVEGF bevacizumab | |
| | 5 | | Paclitaxel | approved, vet_approved | Phase 3, Phase 2, Phase 1, Early Phase 1 | 2864 | 33069-62-4 | 36314 | (2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine 157069-30-2 33069-62-4 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv. 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv. 7-Epi-Paclitaxel 7-Epi-Taxol 7-Epipaclitaxel 7-Epitaxol 7-epi-Paclitaxel 7-epi-Taxol AB00513812 ABI 007 ABI-007 ABI007 AC-675 AC1L1IOG AC1L1VJI AC1L9AVF ACon1_002231 ANX-513 Abraxane Abraxane (TN) Abraxane I.V. Suspension Abraxis BioScience brand of albumin-bound paclitaxel Ambotz33069-62-4 Anzatax Asotax BIDD:PXR0046 BMS 181339-01 BMS-181339 BMS-181339-01 BPBio1_000320 BRD-A23723433-001-01-2 BRD-A28746609-001-04-0 BRD-K62008436-001-03-1 BSPBio_000290 BSPBio_001152 BSPBio_002614 Bio-0076 Bio1_000362 Bio1_000851 Bio1_001340 Bio2_000416 Bio2_000896 Bristaxol C07394 C466458 C47H51NO14 CCRIS 8143 CHEBI:103439 CHEBI:45863 CHEMBL100910 CHEMBL418410 CHEMBL48 CID36314 CID441276 CID4666 CID6713921 CID6915727 CPD-8718 Capxol D00491 DB01229 DHP-107 DHP-208 DRG-0190 DTS-301 DivK1c_000441 EU-0101201 Ebetaxel EmPAC Epitaxol Genaxol Genetaxyl Genexol Genexol-PM HMS1362J13 HMS1568O12 HMS1792J13 HMS1922K08 HMS1990J13 HMS2090D07 HMS2093K15 HMS501G03 HSDB 6839 I06-0014 IDI1_000441 IDI1_002171 Intaxel KBio1_000441 KBio2_000492 KBio2_002016 KBio2_002509 KBio2_003060 KBio2_004584 KBio2_005077 KBio2_005628 KBio2_007152 KBio2_007645 KBio3_000903 KBio3_000904 KBio3_001834 KBio3_002987 KBioGR_000492 KBioGR_001893 | KBioGR_002509 KBioSS_000492 KBioSS_002016 KBioSS_002517 LMPR0104390001 LS-31070 LipoPac Lopac0_001201 MBT 0206 MEGxp0_001940 MLS000863266 MLS001077297 MLS002154218 MLS002172439 MLS002695976 MPI-5018 Micellar Paclitaxel Mitotax MolPort-001-742-627 MolPort-003-665-783 MolPort-003-932-365 NCGC00024995-02 NCGC00024995-03 NCGC00024995-04 NCGC00024995-05 NCGC00024995-06 NCGC00024995-07 NCGC00164367-01 NCGC00164367-02 NCGC00164367-03 NCI60_000601 NINDS_000441 NK 105 NP-010981 NSC 125973 NSC-125973 NSC125973 NSC358882 Nanotaxel Neuro_000060 Nova-12005 OAS-PAC-100 OncoGel Onxal Onxol Onxol, Taxol, Nov-Onxol, Paclitaxel P1632 Paclical Pacligel Paclitaxel Paclitaxel (JAN/USP) Paclitaxel (JAN/USP/INN) Paclitaxel (Taxol) Paclitaxel [USAN:INN:BAN] Paxceed Paxene Paxoral Plaxicel Praxel Prestwick0_000155 Prestwick1_000155 Prestwick2_000155 Prestwick3_000155 Probes2_000350 QW 8184 S-8184 Paclitaxel Injectable Emulsion S1150_Selleck SDCCGMLS-0066823.P001 SDP-013 SMP1_000228 SMR000394086 SMR000857385 SPBio_000943 SPBio_002229 SPECTRUM1503908 ST50306996 Spectrum2_000872 Spectrum3_001057 Spectrum4_001197 Spectrum5_001491 Spectrum_001536 T 7402 T1912_SIGMA T7191_SIGMA T7402_SIGMA TA1 TAXOL (TN) TAXOL, 10-EPI, TXL TaxAlbin Taxol Taxol A Taxol Konzentrat Taxol.RTM. (Registered Trademark) UNII-P88XT4IS4D UPCMLD-DP108:001 UPCMLD-DP108:002 Vascular Wrap Xorane Yewtaxan abi-007 albumin-bound paclitaxel cMAP_000068 nab-paclitaxel nchembio.188-comp1 nchembio.2007.34-comp9 nchembio.215-comp9 nchembio853-comp6 paclitaxel weekly paclitaxel |
| | 6 | | Cyclophosphamide | approved, investigational | Phase 3, Phase 2, Phase 1 | 2935 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 7 | | Epirubicin | approved | Phase 3, Phase 2, Phase 1 | 394 | 56420-45-2 | 41867 | (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione 4'-Epi-DXR 4'-Epiadriamycin 4'-Epidoxorubicin 4'-epi-DX 4'-epi-Doxorubicin 4'-epidoxorubicin 4-Epidoxorubicin 56390-09-1 56390-09-1 (hydrochloride) 56420-45-2 57918-25-9 AC1L26NP AC1Q6JIV BRN 1445813 C11230 C27H29NO11 CCRIS 2261 CHEBI:47898 CHEMBL417 CID41867 D07901 DB00445 Ellence Epi-DX Epi-Dx Epiadriamycin Epidoxorubicin Epirubicin | Epirubicin (INN) Epirubicin [INN:BAN] Epirubicina Epirubicina [INN-Spanish] Epirubicina [Spanish] Epirubicine Epirubicine [French] Epirubicine [INN-French] Epirubicinum Epirubicinum [INN-Latin] Epirubicinum [Latin] Farmorubicin (TN) HSDB 6962 IMI 28 LS-187190 LS-93992 MLS000759412 NChemBio.2007.10-comp15 NSC 256942 NSC-256942 NSC256942 Pharmorubicin Pfs Pidorubicin Pidorubicina Pidorubicina [INN-Spanish] Pidorubicine Pidorubicine [INN-French] Pidorubicinum Pidorubicinum [INN-Latin] Ridorubicin SMR000466308 Triferric doxorubicin UNII-3Z8479ZZ5X WP 697 | |
| | 8 | | Trastuzumab | approved, investigational | Phase 2, Phase 3, Phase 1 | 784 | 180288-69-1 | 9903 | 180288-69-1 Anti HER2 Anti-erbB2 Monoclonal Antibody D03257 HER2 Monoclonal Antibody Herceptin | Herceptin (TN) Ig gamma-1 chain C region Trastuzumab Trastuzumab (INN) Trastuzumab (genetical recombination) Trastuzumab (genetical recombination) (JAN) trastuzumab | |
| | 9 | | Irinotecan | approved, investigational | Phase 3, Phase 2, Phase 1 | 1123 | 97682-44-5, 100286-90-6 | 60838 | (+)-Irinotecan (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate 1u65 97682-44-5 AC-7469 AC1L1U0Z AC1Q6PGI BRD-K08547377-003-02-4 BSPBio_002346 Bio-0054 Biotecan Biotecan (TN) C16641 C33H38N4O6 CHEBI:105985 CHEMBL481 CID60838 CP0 Campothecin-11 Campto Camptosar | Camptosar, Campto, CPT-11, Irinotecan Camptothecin-11 D08086 DB00762 FT-0083650 HSDB 7607 IRINOTECAN HYDROCHLORIDE Trihydrate IRINOTECAN, CPT-11 Irinotecan (INN) Irinotecan Hcl Irinotecan Hydrochloride Irinotecan Hydrochloride Trihydrate Irinotecan [INN:BAN] Irinotecan hydrochloride Irinotecanum Irinotecanum [INN-Latin] LS-44589 NCI60_005051 NSC728073 S1198_Selleck TL8006026 UNII-7673326042 irinotecan | |
| | 10 | | Sunitinib | approved, investigational | Phase 3, Phase 2 | 510 | 341031-54-7, 557795-19-4 | 5329102 | (2S)-2-hydroxybutanedioic acid 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1) 326914-13-0 341031-54-7 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE 557795-19-4 AC1NS62J AC1O5CMQ AKOS005145765 Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1) CHEBI:38940 CHEBI:550864 CHEMBL1567 CHEMBL535 CID5329102 CID6456015 D06402 D08552 DB01268 DB07417 EN002687 FT-0083555 FT-0083556 I01-1229 K00588a KS-5022 LS-186078 LS-187023 LS-187648 MolPort-003-986-763 N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide NCGC00164631-01 | NSC736511 NSC750690 PDGF TK antagonist PHA-290940AD PNU-290940AD S1042_Selleck ST51053712 SU 011248 SU 11248 SU-010398 SU-011248 L-malate salt SU-11248 SU-11248 L-malate salt SU-11248J SU-12662 SU010398 SU011248 SU011248 L-malate salt SU11248 Su-011248 Sunitanib Sunitinib Sunitinib (INN) Sunitinib (free base) Sunitinib malate Sunitinib malate (JAN/USAN) Sunitinib malate [USAN] Sunitinibum Sutent Sutent (TN) Sutent, SU-11248 TL8002546 UNII-LVX8N1UT73 UNII-V99T50803M sunitinib sunitinibum | |
| | 11 | | Pancrelipase | approved | Phase 3, Phase 2, Phase 1 | 970 | 53608-75-6 | | 1,4-alpha-D- glucan glucanohydrolase PA | Pancreatic alpha-amylase precursor Pancrelipase (amylase lipase protease) |
| | 12 | | Sirolimus | approved, investigational | Phase 3, Phase 1, Phase 2 | 1940 | 53123-88-9 | 5284616, 6436030, 46835353 | (-)-Rapamycin (-)-rapamycin 1fkb 1pbk 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 53123-88-9 A422989, NSC226080 AC-722 AC1L1JH9 AC1L7MJ9 AC1L9ZMV AY 22989 AY-22989 AY22989 Ambotz53123-88-9 Antibiotic AY 22989 BIDD:PXR0165 Bio1_000293 Bio1_000782 Bio1_001271 Bio2_000375 Bio2_000855 BiomolKI2_000084 C07909 C51H79NO13 CBiol_002007 CCRIS 9024 CHEBI:100923 CHEBI:9168 CHEMBL413 CID10213190 CID10795871 CID11949238 CID11959112 CID313006 CID478951 CID5040 CID5284616 CID5358081 CID5374464 CID5460439 CID5497196 CID5924240 CID6436030 CID6610270 CID6610346 CID6711160 CID6713081 CID9833581 CID9854379 CID9854380 CID9962926 CID9962928 D00753 DB00877 DE-109 DivK1c_006936 | FT-0082351 HMS2089A21 HSDB 7284 KBio1_001880 KBio2_000410 KBio2_002978 KBio2_005546 KBio3_000779 KBio3_000780 KBioGR_000410 KBioSS_000410 LCP-Siro LMPK06000003 LS-143290 MLS000028373 MS-R001 MolMap_000043 MolPort-003-959-433 NCGC00021305-05 NCI60_001851 NCIMech_000355 NSC 226080 NSC226080 Perceiva QTL1_000069 R0395_SIAL R0395_SIGMA RAP RAPA RPM Rapammune Rapamune Rapamune (TN) Rapamycin Rapamycin (TN) Rapamycin C-7, analog 4 Rapamycin Immunosuppressant Drug Rapamycin from Streptomyces hygroscopicus S1039_Selleck SIIA 9268A SILA 9268A SILA9268A SMP1_000255 SMR000058564 Sirolimus Sirolimus (RAPAMUNE) Sirolimus (USAN/INN) Sirolimus [USAN:BAN:INN] Sirolimus, Rapamune,Rapamycin SpecPlus_000840 UNII-W36ZG6FT64 UNM-0000358684 WY-090217 Wy 090217 heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy nchembio.100-comp4 nchembio.2007.42-comp2 nchembio.79-comp1 nchembio762-comp1 nchembio883-comp3 rapamycin sirolimus |
| | 13 | | Miconazole | approved, investigational, vet_approved | Phase 3, Phase 1, Phase 2 | 3706 | 22916-47-8 | 4189 | (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole 1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole 22832-87-7 (NITRATE) 22916-47-8 75319-47-0 AB00053500 AC1L1HM1 AKOS001574474 Aflorix(nitrate) Albistat(nitrate) Andergin(nitrate) BPBio1_000279 BRD-A82396632-001-03-0 BRD-A82396632-008-02-7 BRN 0965511 BSPBio_000253 BSPBio_002033 CCRIS 7924 CHEBI:6923 CHEMBL91 CID4189 CPD-4501 Conofite(nitrate) D00416 DB01110 Dactarin Daktarin IV Daktarin iv DivK1c_000156 EINECS 245-324-5 Epi-Monistat(nitrate) Femizol-M Florid(nitrate) Gyno-Daktar(nitrate) HMS1568M15 HMS2090B21 I14-14342 IDI1_000156 Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI) KBio1_000156 KBio2_001445 KBio2_004013 KBio2_006581 KBio3_001533 KBioGR_000581 KBioSS_001445 LS-78378 Lotrimin AF(nitrate) MCZ MJR 1762 MLS002222203 Micantin (nitrate) Miconasil Nitrate | Miconazol Miconazol [INN-Spanish] Miconazole Miconazole (JP15/USP/INN) Miconazole 3 Miconazole 3 Combination Pack Miconazole 7 Combination Pack Miconazole [USAN:BAN:INN:JAN] Miconazole nitrate salt Miconazole-7 Miconazolo Miconazolo [DCIT] Miconazolum Miconazolum [INN-Latin] Micozole Minostate MolPort-002-557-553 Monazole 7 Monista (nitrate) Monistat Monistat (TN) Monistat 1 Combination Pack Monistat 3 Dual-Pak Monistat 3 Vaginal Ovules Monistat 5 Tampon Monistat 7 Dual-Pak Monistat 7 Vaginal Suppositories Monistat Dual- PAK Monistat IV Monistat iv (TN) Monistat iv (tn) Monistat-Derm NCI60_001353 NCI60_001380 NINDS_000156 NSC 170986 NSC169434 NSC170986 Novo-Miconazole Vaginal Ovules Oprea1_091955 Prestwick0_000067 Prestwick1_000067 Prestwick2_000067 Prestwick3_000067 Prestwick_335 R 18134 R-14,889 SMR001307249 SPBio_000976 SPBio_002174 STK834405 STOCK1S-93556 Spectrum2_001048 Spectrum3_000507 Spectrum4_000061 Spectrum5_001297 Spectrum_000965 UNII-7NNO0D7S5M Vusion Zimycan imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI) miconazole | |
| | 14 | | Estradiol | approved, investigational, vet_approved | Phase 3, Phase 2, Phase 1 | 1318 | 50-28-2 | 5757, 53477783 | (+)-3,17b-Estradiol (17b)-Estra-1,3,5(10)-triene-3,17-diol (17beta)-Estra-1,3,5(10)-triene-3,17-diol .alpha.-Estradiol .alpha.-Oestradiol .beta.-Estradiol .beta.-Oestradiol 1,3,5[10]-Estratriene-3,17beta-diol 3-sulfate 1,3,5[10]-Estratriene-3,17beta-diol 3-sulphate 13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol 17 beta-Estradiol 17-.BETA.-Estradiol 17-E 17-beta 17-beta-OH-estradiol 17-beta-estradiol 17.beta.-Estradiol 17.beta.-Oestradiol 17E 17b-Estradiol 17b-Oestradiol 17beta Oestradiol 17beta oestradiol 17beta-Estra-1,3,5(10)-triene-3,17-diol 17beta-Estradiol 17beta-Oestradiol 1jgl 1qkt 1qku 2d06 3,17-Epidihydroxyestratriene 3,17-beta-Estradiol 3,17-beta-Oestradiol 3,17.beta.-Estradiol 3,17b-Dihydroxyestra-1,3,5(10)-triene 3,17b-Estradiol 3,17beta-Estradiol 3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulfate 3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulphate 50-28-2 73459-61-7 873662-39-6 AC-10460 AC1L1L2K Aerodiol Agofollin Alora Altrad Amnestrogen Aquadiol B-Estradiol BEDOs BIDD:ER0125 BIDD:PXR0065 BPBio1_000532 BSPBio_000482 BSPBio_001065 Bardiol Benzhormovarine Beta-estradiol Bio-0812 Bio-E-Gel Bio1_000403 Bio1_000892 Bio1_001381 Bio2_000363 Bio2_000843 C00951 C18H24O2 CCRIS 280 CHEBI:16469 CHEMBL135 CID5757 CMC_11154 CPD-352 CPD000059126 Climaderm Climara Climara (TN) Climara Forte Compudose Compudose 200 Compudose 365 Corpagen D-3,17beta-Estradiol D-Estradiol D-Oestradiol D00105 DB00783 Dermestril Destradiol Dihydro-Theelin Dihydrofollicular hormone Dihydrofolliculin Dihydromenformon Dihydrotheelin Dihydroxyesterin Dihydroxyestrin Dihydroxyoestrin Dimenformon Diogyn Diogynets Divigel Divigel (TN) E 2 E 8875 E(sub 2) E0025 E1024_SIGMA E1132_SIGMA E2257_SIGMA E2758_SIGMA E8875_SIGMA EINECS 200-023-8 EU-0100503 Elestrin Encore Epiestriol 50 Esclim Estra-1,3,5(10)-triene-3,17b-diol Estrace Estrace (TN) Estraderm Estraderm (TN) Estraderm MX Estraderm TTS Estraderm TTS 100 Estraderm TTS 50 Estradiol Estradiol [USAN:INN] Estradiol-17 beta Estradiol-17-beta Estradiol-17.beta. Estradiol-17beta Estradiol-3,17beta Estradiolo Estradiolo [DCIT] Estradiolum Estradiolum [INN] Estradot Estraldine Estrapak 50 Estrasorb Estrasorb (TN) Estreva Estrifam Estring Estring (TN) Estring Vaginal Ring Estring vaginal ring Estroclim Estroclim 50 Estrodiolum Estrofem 2 Estrofem Forte Estrogel | Estrogel (TN) Estrogel HBF Estrovite Evamist Evorel Extrasorb Femanest Femestral Femestrol Femogen Fempatch Femtrace Femtran Follicyclin Gelestra Ginedisc Ginosedol GynPolar Gynergon Gynestrel Gynodiol Gynoestryl HMS1362E07 HMS1569I04 HMS1792E07 HMS1990E07 HMS2051C17 HMS2090E18 HSDB 3589 IDI1_002118 Innofem Innofem (TN) KBio2_000405 KBio2_002269 KBio2_002973 KBio2_004837 KBio2_005541 KBio2_007405 KBio3_000769 KBio3_000770 KBio3_002749 KBioGR_000405 KBioGR_002269 KBioSS_000405 KBioSS_002270 LMST02010001 LS-137 Lamdiol Lio-Oid Lopac0_000503 MLS000069494 MLS000758312 MLS001076331 Macrodiol Macrol Menest Menorest Menostar Microdiol MolPort-001-794-632 NCGC00091544-00 NCGC00091544-01 NCGC00091544-02 NCGC00091544-04 NCGC00091544-05 NCGC00091544-06 NCGC00091544-07 NCGC00091544-08 NCGC00091544-09 NCGC00091544-12 NCGC00179321-01 NCGC00179321-02 NSC-9895 NSC9895 Nordicol Oesclim Oestergon Oestra-1,3,5(10)-triene-3,17b-diol Oestradiol Oestradiol Berco Oestradiol R Oestradiol-17-beta Oestradiol-17.beta. Oestradiol-17beta Oestradiolum Oestrogel Oestroglandol Oestrogynal Ovahormon Ovasterol Ovastevol Ovociclina Ovocyclin Ovocycline Ovocylin Perlatanol Polyestradiol Prestwick0_000441 Prestwick1_000441 Prestwick2_000441 Prestwick3_000441 Prestwick_207 Primofol Profoliol Profoliol B Progynon Progynon DH Progynon-DH S-21400 S1709_Selleck SAM001247032 SK-Estrogens SL-1100 SMP1_000121 SMR000059126 SPBio_002421 Sandrena 1 Sandrena Gel Sisare Gel Spectrum5_002055 Syndiol Systen Tradelia Trial SAT Trocosone UNII-4TI98Z838E VIVELLE-DOT Vagifem Vagifem (TN) Vivelle Vivelle (TN) Zerella Zesteem Zesteen Zumenon [2,4,6,7-3H]-E2 [3H]-estradiol [3H]]estradiol b-Estradiol beta-Estradiol beta-Estradiol 3-sulfate beta-Estradiol 3-sulphate bmse000642 cMAP_000005 cis-Estradiol cis-Oestradiol component of Menrium delta-Estradiol delta-Oestradiol estradiol estradiol-17beta nchembio.168-comp3 nchembio.76-comp2 nchembio775-comp2 nchembio794-comp6 nchembio860-comp1 progynon | |
| | 15 | | Everolimus | approved | Phase 3, Phase 1, Phase 2 | 1940 | 159351-69-6 | 6442177 | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy 07741_FLUKA 159351-69-6 40-O-(2-hydroxyethyl)-rapamycin 42-O-(2-Hydroxyethyl)rapamycin Afinitor CERTICAN(R) CHEMBL1201755 Certican D02714 DB01590 | Everolimus Everolimus (JAN/USAN/INN) Everolimus [USAN] LS-143292 MolPort-003-847-342 MolPort-003-925-588 NCGC00167512-01 NVP-RAD-001 RAD 001 RAD-001 RAD-001C RAD001 RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus S1120_Selleck SDZ-RAD UNII-9HW64Q8G6G Zortress everolimus |
| | 16 | | Tamoxifen | approved | Phase 3, Phase 2 | 390 | 10540-29-1 | 2733526 | (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine (Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC) (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine ,citrate 1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene 1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene 10540-29-1 1ya4 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine 54965-24-1 (citrate) AC1MBZ3R Apo-Tamox Apo-tamox BIDD:ER0008 BIDD:GT0009 BIDD:PXR0003 BPBio1_000278 BRD-K93754473-001-02-9 BRD-K93754473-048-05-3 BSPBio_000252 BSPBio_001150 BSPBio_001982 C07108 C26H29NO CCRIS 3275 CHEBI:41774 CHEMBL83 CID2733526 Citofen Crisafeno D08559 DB00675 Diemon EINECS 234-118-0 Gen-Tamoxifen Gen-tamoxifen HMS1362J11 HMS1792J11 HMS1990J11 HMS2090N08 HSDB 6782 ICI 47699 ICI-46,474 ICI-47699 IDI1_000258 IDI1_002170 Istubol Kessar L024126 LS-393 Lopac0_001203 MLS001332535 MLS001332536 MolPort-003-850-384 | NCGC00024928-01 NCGC00024928-03 NCGC00024928-04 NCGC00024928-05 NCGC00024928-07 NCGC00024928-08 NCGC00024928-09 NCGC00024928-12 NSC727681 Noltam Nolvadex Nolvadex-D Nourytam Novaldex Novo-Tamoxifen Oncomox PMS-Tamoxifen Pms-Tamoxifen Prestwick2_000146 Prestwick3_000146 QTL1_000079 Retaxim SMR000059172 ST50511785 Spectrum5_001417 Spectrum5_002043 T5648_SIGMA TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)) TRANS FORM OF TAMOXIFEN Tamizam Tamofen Tamone Tamoplex (TN) Tamoxasta Tamoxen Tamoxifen Tamoxifen (INN) Tamoxifen (TN) Tamoxifen (Z) Tamoxifen Citrate Tamoxifen [INN:BAN] Tamoxifen and its salts Tamoxifene Tamoxifene [INN-French] Tamoxifeno Tamoxifeno [INN-Spanish] Tamoxifenum Tamoxifenum [INN-Latin] Tamoxifène Tocris-0999 Tomaxithen Trans-Tamoxifen UNII-094ZI81Y45 UPCMLD-DP027 Valodex Zemide cMAP_000044 nchembio.140-comp7 nchembio.76-comp1 nchembio732-comp3 tamoxifen trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine trans-Tamoxifen | |
| | 17 | | Fulvestrant | approved, investigational | Phase 3, Phase 2, Phase 1 | 202 | 129453-61-8 | 104741, 17756771 | (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol 129453-61-8 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol AC-4693 AC1L2XEN AstraZeneca brand of fulvestrant BIDD:ER0348 BIDD:PXR0136 C070081 C32H47F5O3S CCRIS 8741 CHEBI:404798 CHEMBL1358 CID104741 D01161 DB00947 Faslodex Faslodex (TN) | Faslodex(ICI 182,780) Faslodex, ICI 182780, Fulvestrant Fulvestrant Fulvestrant (JAN/USAN/INN) Fulvestrant [USAN] HMS2090N22 HSDB 7658 I06-1109 ICI 182,780 ICI 182,789 ICI-182780 Ici 182780 LS-64781 NCGC00164789-02 NSC719276 S1191_Selleck UNII-22X328QOC4 ZD 182780 ZD-182780 ZD-9238 ZM 182780 ZM-182780 fulvestrant nchembio.168-comp5 nchembio.76-comp5 nchembio775-comp4 |
| | 18 | | Progesterone | approved, vet_approved | Phase 3, Phase 1, Phase 2, Early Phase 1 | 559 | 57-83-0 | 5994 | (S)-4-Pregnene-3,20-dione (S)-Pregn-4-en-3,20-dione (S)-Progesterone .beta.-Progesterone .delta.(sup4)-Pregnene-3,20-dione .delta.4-Pregnene-3,20-dione 17.alpha.-Progesterone 17a-Progesterone 17alpha-Progesterone 17alpha-progesterone 17α-progesterone 1dbb 1h60 257630-50-5 3,20-Pregnene-4 32104FB6-BF81-4F6E-83C2-024DEEAEB272 4-Pregnen-3,20-dione 4-Pregnene-3,20-dione 46665_FLUKA 46665_RIEDEL 57-83-0 753497-20-0 8012-32-6 8023-13-0 AC-700 AC1L1LKF AI3-51682 Agolutin Akrolutin BB_NC-0185 BHR-100 BIDD:ER0547 BIDD:PXR0094 BPBio1_000676 BRD-K64994968-001-03-6 BSPBio_000614 Bio-luton C00410 CCRIS 533 CHEBI:17026 CHEMBL103 CID5994 CIDR CMC_13406 COL-1620 CPD000058345 Colprosterone Corlutin Corlutina Corluvite Corporin Corpus Luteum Hormone Corpus luteum hormone Crinone Crinone (TN) Crinone progesterone gel Curretab Cyclogest Cyclogesterin D00066 D4-Pregnene-3,20-dione DB00396 DR-2011 Delalutin Delta(4)-pregnene-3,20-dione Duraprogen EINECS 200-350-6 ETI-411 EU-0100895 Endometrin Estima FE-999913 Flavolutan Fologenon Gelbkoerperhormon Gesterol Gesterol 100 Gesterol 50 Gestiron Gestone Gestormone Gestron Glanducorpin Gynlutin Gynoluton Gynolutone HMS1569O16 HMS2051O05 HMS2090J07 HSDB 3389 Hormoflaveine Hormoluton Hydroxyprogesterone Caproate Hydroxyprogesterone Caproic acid LMST02030159 LS-234 Lingusorbs Lipo-Lutin Lipolutin Lopac0_000895 Lucorteum Lucorteum Sol Lucorteum sol Lugesteron Luteal hormone Luteinique Luteocrin normale Luteodyn Luteogan Luteohormone Luteol Luteol (VAN) Luteopur Luteosan Luteostab Luteovis Luteum Lutex Lutidon Lutin Lutinus Lutociclina Lutocuclin M Lutocyclin Lutocyclin M | Lutocyclin m Lutocylin Lutocylol Lutoform Lutogyl Lutogynon Lutren Lutromone MLS000028517 MLS000758277 MLS001074187 MLS002222367 MPA Membrettes Methylpregnone Micronized Progesterone MolPort-001-794-643 NCGC00022185-03 NCGC00022185-04 NCGC00022185-05 NCGC00022185-06 NCGC00022185-07 NCGC00022185-08 NCGC00022185-09 NCGC00090798-01 NCGC00090798-02 NCI60_042166 NSC 64377 NSC 9704 NSC-9704 NSC64377 NSC9704 Nalutron Natural Progesterone P 0130 P0130_SIGMA P0478 P3972_SIGMA P6149_SIGMA P7556_ALDRICH P7556_SIGMA P8783_SIGMA P9776_SIGMA PROGESTERONE Percutacrine Percutacrine Luteinique Piaponon Pranone Pregn-4-en-3,20-dione Pregn-4-ene-3,20-dione Pregnene-3,20-dione Pregnenedione Prestwick0_000477 Prestwick1_000477 Prestwick2_000477 Prestwick3_000477 Prestwick_411 Primolut Prochieve Progeffik Progekan Progestan Progestasert Progesterol Progesteron Progesterona Progesterona [INN-Spanish] Progesterone Progesterone (JP15/USP/INN) Progesterone [INN:BAN:JAN] Progesterone [Progestins] Progesterone, water-soluble Progesterone-Water Soluble Progesterone: HBC complex Progesteronum Progesteronum [INN-Latin] Progestin Progestogel Progestol Progeston Progestone Progestosol Progestrel Progestron Progestronol Progestérone Projestaject Prolets Prolidon Prolutin Proluton Prolutone Prometrium Prometrium (TN) Prontogest Protormone S00293 S1705_Selleck SAM001247039 SMR000058345 SMR000653542 SPBio_002553 SR-01000000088 SR-01000000088-5 Spectrum5_002053 Syngesterone Syngestrets Synovex S Syntolutan U 3672 UNII-4G7DS2Q64Y Utrogest Utrogestan Vitarrine WLN: L E5 B666 OV MUTJ A1 E1 FV1 ZINC04428529 beta-Progesterone bmse000482 component of Cyclogesterin corpus luteum hormone delta(4)-Pregnene-3,20-dione delta(Sup 4)-Pregnene-3,20-dione delta(Sup4)-pregnene-3,20-dione delta(sup 4)-Pregnene-3,20-dione delta4-Pregnene-3,20-dione luteohormone nchembio.2007.53-comp14 |
| | 19 | | Lenograstim | approved | Phase 3, Phase 2, Phase 1 | 1220 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 20 | | Vinorelbine | approved, investigational | Phase 3, Phase 2, Phase 1 | 374 | 71486-22-1 | 60780, 44424639 | 5'-Noranhydrovinblastine 71486-22-1 AC1L1KVK AC1L1TWQ AC1L75Q4 ANX-530 Ambap71486-22-1 BIDD:PXR0186 C45H54N4O8 CHEBI:480999 CHEMBL607994 CID355119 CID5311497 CID5672 CID60780 CID6426842 D08680 DB00361 Eunades Exelbine HMS2090E13 HSDB 7665 I06-0084 I06-0085 KW 2307 KW 2307 base KW-2307 | LS-97533 MolPort-006-822-661 MolPort-006-823-869 NCGC00165966-02 NVB Navelbine Navelbine (TN) Navelbine Base Navelbine base Nor-5'-anhydrovinblastine SDP-012 UNII-Q6C979R91Y Vinorelbin Vinorelbina Vinorelbina [Spanish] Vinorelbine Vinorelbine (INN) Vinorelbine Bitartrate Vinorelbine Ditartarate Vinorelbine Ditartrate Vinorelbine Tartrate Vinorelbine [INN:BAN] Vinorelbine ditartrate Vinorelbine tartrate Vinorelbinum Vinorelbinum [Latin] methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate vinorelbine |
| | 21 | | Vinblastine | approved | Phase 3, Phase 2, Phase 1 | 420 | 865-21-4 | 13342, 241903 | (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE (2xi,3beta,4'beta,19xi)-vincaleukoblastine (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate 143-67-9 1z2b 29060-LE 865-21-4 AC-20335 AC1L21JC AC1L68D2 AC1MXZJ2 BIDD:PXR0201 BRD-K01188359-065-02-5 BSPBio_001228 BSPBio_003594 Bio-0111 C07201 C46H58N4O9 CCRIS 9002 CHEBI:171516 CHEBI:27375 CHEMBL159 CHEMBL607706 CID13342 CID241903 CID3823887 CID6710780 D08675 DB00570 EINECS 212-734-0 HMS2090K05 HSDB 3263 KBio3_003033 LS-1859 LS-187263 MolPort-002-518-262 | MolPort-005-910-359 NCGC00022585-04 NCGC00181127-01 NCI-C04842 NCI60_004200 NChemBio.2007.10-comp22 NDC 0002-1452-01 NSC 47842 Neuro_000020 Nincaluicolflastine Rozevin SPBio_000680 STOCK1N-38480 Spectrum2_000890 Spectrum3_001994 UNII-5V9KLZ54CY VLB VR-8 Velban Velbe Vinblastin Vinblastina Vinblastina (TN) Vinblastina [DCIT] Vinblastina [Dcit] Vinblastine Vinblastine (INN) Vinblastine Sulfate Vinblastine [INN:BAN] Vinblastinum Vinblastinum [INN-Latin] Vincaleucoblastin Vincaleucoblastine Vincaleukoblastine Vincoblastine nchembio873-comp22 vinblastine | |
| | 22 | | Capecitabine | approved, investigational | Phase 3, Phase 2, Phase 1 | 1342 | 154361-50-9 | 60953 | (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester 154361-50-9 158798-73-3 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine AC1L1U83 AC1Q4KU8 Ambap154361-50-9 C110904 C12650 C15H22FN3O6 CAPE CAPECITABINE CHEBI:31348 CHEMBL1773 CID60953 Capecitabin Capecitabina Capecitabine (JAN/USAN/INN) Capecitabine [USAN] Capecitabinum Capecitibine Capiibine Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester Caxeta | D01223 DB01101 FT-0082472 HSDB 7656 LS-59070 MolPort-005-938-254 N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate R-340 R340 RG-340 Ro 09-1978 Ro 09-1978/000 Ro-09-1978 Ro-09-1978/000 S1156_Selleck UNII-6804DJ8Z9U Xabine Xeloda Xeloda (TN) Xeloda, Captabin, Capecitabine ZINC03806413 capecitabina capecitabine capecitabinum pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate |
| | 23 | | Octreotide | approved, investigational | Phase 2, Phase 3, Phase 1 | 223 | 83150-76-9 | 383414, 6400441 | (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide 79517-01-4 (acetate salt) 83150-76-9 AC1L1GVU AC1L8LCD AC1L9M4X C07306 C5H12O2.C4H10 CHEBI:427278 CHEBI:611465 CHEMBL1680 CID383414 CID448601 CID54374 D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide D00442 DRG-0115 HMS2090C09 HS-2020 | L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R* L000453 LS-177735 LS-187135 Longastatin NCGC00181796-01 NCI60_025753 Octreotida Octreotida [Spanish] Octreotide Octreotide (USAN/INN) Octreotide Acetate Salt Octreotide [USAN:INN:BAN] Octreotide-LAR Octreotidum Octreotidum [Latin] Octrotide SAN 201-995 SM 201-995 SMS 201-995 SMS-201-995 Sandostatine Sandoz 201-995 UNII-RWM8CCW8GP nchembio.184-comp3 zacycloicosane-4-carboxamide acetate |
| | 24 | | Zoledronic acid | approved | Phase 2, Phase 3 | 294 | 118072-93-8 | 68740 | (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid 118072-93-8 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid AC-1092 AC1L2ACJ AC1Q6RN3 AKOS005145739 Aclasta Anhydrous Zoledronic Acid BIDD:GT0292 BIDD:PXR0134 Bio-0112 Bisphosphonate 3 C088658 CGP 42'446 CGP 42446 CGP 42446A CGP-42'446 CGP-42446 CHEBI:46557 CHEMBL924 CID68740 D08689 DB00399 | FT-0082657 HMS2089O09 I06-0710 KS-1132 LS-181815 MolPort-002-885-874 MolPort-003-850-890 NCGC00159521-02 NCGC00159521-03 NSC721517 Novartis brand of zoledronic acid Reclast Reclast (TN) S00092 S1314_Selleck UNII-70HZ18PH24 ZOL Zol Zoledronate Zoledronic Acid Anhydrous Zoledronic Acid, Anhydrous Zoledronic acid Zoledronic acid (INN) Zoledronic acid [USAN:INN] Zometa Zometa (Novartis) Zometa (TN) Zometa Concentrate Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) | |
| | 25 | | Levoleucovorin | approved | Phase 3, Phase 2, Phase 1 | 728 | 68538-85-2 | | (6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid (6S)-5-formyltetrahydrofolic acid (6S)-Folinic acid (6S)-Leucovorin | (S)-Leucovorin Citrovorum factor L-Folinic acid Levofolene Levofolinic acid N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid |
| | 26 | | Metformin | approved | Phase 3, Phase 2, Phase 1 | 1803 | 657-24-9 | 14219, 4091 | 1,1-Dimethyl biguanide 1,1-Dimethylbiguanide 3-(diaminomethylidene)-1,1-dimethylguanidine 657-24-9 AC1L1HE4 AKOS000121065 Apo-Metformin BIDD:GT0697 BPBio1_000009 BRD-K79602928-003-04-1 BSPBio_000007 BSPBio_002314 C07151 C4H11N5 CAS-1115-70-4 CCRIS 9321 CHEBI:6801 CHEMBL1431 CID4091 D04966 DB00331 DMGG Diabetosan Diabex Dimethylbiguanid Dimethylbiguanide Dimethylbiguanidine Dimethyldiguanide Dimethylguanylguanidine EINECS 211-517-8 Fluamine Flumamine Fortamet Gen-Metformin Glifage Gliguanid Glucophage Glucophage XR Glumetza Glycon HMS2089D19 HSCI1_000295 Haurymelin Haurymellin Islotin KBio2_002310 KBio2_004878 KBio2_007446 KBio3_002790 KBioGR_002310 | KBioSS_002312 LA-6023 LS-43899 Melbin Metformin Metformin (USAN/INN) Metformin HCL Metformin [USAN:INN:BAN] Metformina Metformina [DCIT] Metformina [Spanish] Metformine Metformine [INN-French] Metformine pamoate Metforminum Metforminum [INN-Latin] Metiguanide MolPort-002-929-560 MolPort-004-288-389 MolPort-005-767-418 Mylan-Metformin N,N-Dimethylbiguanide N,N-Dimethyldiguanide N,N-Dimethylimidodicarbonimidic diamide N,N-dimethylimidodicarbonimidic diamide N1,N1-Dimethylbiguanide NCGC00016564-01 NCGC00016564-02 NCGC00016564-03 NNDG Novo-Metformin Nu-Metformin PMS-Metformin Prestwick0_000004 Prestwick1_000004 Prestwick2_000004 Prestwick3_000004 Ran-Metformin Ratio-Metformin Riomet S2483_Selleck SPBio_001928 STK011633 Sandoz Metformin Siofor T5895664 Teva-Metformin UNII-9100L32L2N ZINC12859773 cMAP_000016 metformin metformin hydrochloride |
| | 27 | | Fentanyl | approved, illicit, investigational, vet_approved | Phase 3 | 821 | 437-38-7 | 3345 | 1-Phenethyl-4-(N-phenylpropionamido)piperidine 1-Phenethyl-4-N-propionylanilinopiperidine 1-phenethyl-4-N-propionylanilinopiperidine 437-38-7 5-22-08-00049 (Beilstein Handbook Reference) 80832-90-2 990-73-8 (citrate) AC1L1FQ2 Actiq BIDD:GT0555 BRN 0494484 CHEBI:119915 CHEMBL596 CID3345 D00320 DB00813 Duragesic Duragesic (TN) Duragesic-100 Duragesic-12 Duragesic-25 Duragesic-50 Duragesic-75 Durogesic EINECS 207-113-6 Fentanest Fentanil Fentanil [DCIT] Fentanila Fentanila [INN-Spanish] Fentanilo Fentanyl Fentanyl (JAN/USAN/INN) Fentanyl CII Fentanyl [INN:BAN] Fentanyl citrate Fentanyl-100 Fentanyl-12 Fentanyl-25 | Fentanyl-50 Fentanyl-75 Fentanylum Fentanylum [INN-Latin] HSDB 3329 IONSYS JNS020QD L001275 LS-124439 Matrifen MolPort-003-847-369 N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-Phenethyl-4-piperidyl)propionanilide N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-phenethyl-4-piperidyl)propionanilide N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide N-Phenethyl-4-(N-propionylanilino)piperidine N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenethyl-4-(N-propionylanilino)piperidine N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide NCGC00168252-01 Nasalfent Oprea1_152073 Oprea1_207148 PDSP1_000860 PDSP2_000846 Pentanyl Phentanyl Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI) R 4263 Rapinyl Sentonil Sublimase Sublimaze UNII-UF599785JZ fentanyl | |
| | 28 | | Somatostatin | approved | Phase 2, Phase 3, Phase 1 | 237 | 38916-34-6, 51110-01-1 | 53481605 | growth hormone-inhibiting hormone (GHIH) | somatotropin release-inhibiting factor (SRIF) somatotropin release-inhibiting hormone | |
| | 29 | | Prednisone | approved, vet_approved | Phase 3 | 1398 | 53-03-2 | 5865 | (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione .delta. E .delta.(sup1)-Cortisone .delta.-Cortelan .delta.-Cortisone .delta.-Cortone .delta.-E .delta.1-Cortisone .delta.1-Dehydrocortisone .delta.sone 1,2-Dehydrocortisone 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione 1-Cortisone 1-Dehydrocortisone 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione 53-03-2 68-59-7 81552_FLUKA AC-11112 AC1L1LB2 AC1Q29EZ ACon0_000082 ACon1_000297 AI3-52939 Adasone Ancortone Apo-Prednisone Apo-prednisone BPBio1_000323 BRD-K85883481-001-04-2 BSPBio_000293 Betapar Bicortone Bio-0649 C07370 C21H26O5 CCRIS 2646 CHEBI:8382 CHEMBL635 CID5865 CPD001227202 Cartancyl Colisone Cortan Cortancyl Cortidelt Cotone DB00635 Dacorten Dacortin Decortancyl Decortin Decortisyl Dehydrocortisone Dekortin Delcortin Dellacort Dellacort A Delta Cortelan Delta E Delta E. Delta-Cortelan Delta-Dome Delta-cortelan Delta-cortisone Delta-cortone Delta-dome Deltacortene Deltacortisone Deltacortone Deltasone Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone Deltison Deltisona Deltisone Deltra Di-Adreson Diadreson EINECS 200-160-3 Econosone Encorton Encortone Enkortolon Enkorton Fernisone Fiasone HMS1568O15 HMS2090J13 HSDB 3168 Hostacortin In-Sone Incocortyl | Juvason Kortancyl LMST02030180 LS-1325 Liquid Pred Lisacort Lodotra MEGxm0_000443 MLS001061265 MLS001304073 MLS001335907 MLS001335908 MLS002154191 MLS002207083 Me-Korti Metacortandracin Meticorten Meticorten (Veterinary) Metrevet (Veterinary) MolPort-001-740-041 NCGC00090766-01 NCGC00090766-02 NCGC00090766-03 NCI-C04897 NCI60_000008 NSC 10023 NSC10023 Nisona Nizon Novoprednisone Nurison Orasone Origen Prednisone P1276 P6254_SIGMA PRD Panafcort Panasol Paracort Parmenison Pehacort Precort Predeltin Prednicen-M Prednicorm Prednicort Prednicot Prednidib Prednilonga Prednison Prednisona Prednisona [INN-Spanish] Prednisone Prednisone Intensol Prednisone [INN:BAN] Prednisonum Prednisonum [INN-Latin] Prednitone Prednizon Prednovister Presone Prestwick0_000077 Prestwick1_000077 Prestwick2_000077 Prestwick3_000077 Prestwick_405 Pronison Pronisone Rectodelt Retrocortine S1622_Selleck SAM002264641 SK-Prednisone SMR000718760 SMR001227202 SPBio_002214 Servisone Sone Sterapred Supercortil U 6020 UNII-VB0R961HZT Ultracorten Ultracortene WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ Winpred Wojtab ZINC03875357 Zenadrid Zenadrid (veterinary) Zenadrid [veterinary] delta cortelan delta(sup 1)-Cortisone delta(sup 1)-Dehydrocortisone delta-1-Cortisone delta-1-Dehydrocortisone delta-Cortisone delta-Cortone | |
| | 30 | | Anastrozole | approved, investigational | Phase 3, Phase 2 | 279 | 120511-73-1 | 2187 | .alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile 1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl) 120511-73-1 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile) 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile) 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile AC-4234 AC1L1D49 Anastrazole Anastrole Anastrozol Anastrozole (JAN/USAN/INN) Anastrozole [USAN:INN:BAN] Arimidex Arimidex (TN) Arimidex (Zeneca) Arimidex, Anastrozole Asiolex Astra brand of anastrozole AstraZeneca brand of anastrozole C08159 C090450 C17H19N5 CHEBI:2704 CHEMBL1399 CID2187 CPD000466301 | D00960 DB01217 HMS2052M11 HMS2089N10 HSDB 7462 I06-0021 ICI D1033 ICI-D 1033 ICI-D1033 LS-29563 MLS000759396 MLS001424217 MolPort-005-933-078 NCGC00164619-01 NSC719344 S1188_Selleck SAM001246525 SBB066057 SMR000466301 UNII-2Z07MYW1AZ ZD 1033 ZD-1033 ZD1033 ZINC00000941 Zeneca ZD 1033 Zeneca brand of anastrozole alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile anastrazole anastrozole |
| | 31 | | Denosumab | approved | Phase 3, Phase 2 | 138 | 615258-40-7 | | 615258-40-7 AMG-162 D03684 Denosumab | Denosumab (USAN) Denosumab (genetical recombination) Denosumab (genetical recombination) (JAN) Prolia Xgeva | |
| | 32 | | lanreotide | approved | Phase 2, Phase 3 | 86 | 108736-35-2 | | | Lanreotide acetate Somatuline Depot | |
| | 33 | | Cetuximab | approved | Phase 3, Phase 1, Phase 2 | 752 | 205923-56-4 | 56842117, 2333 | 205923-56-4 Anti EGFR Cetuximab Cetuximab (USAN/INN) Cetuximab (genetical recombination) Cetuximab (genetical recombination) (JAN) | Cetuximabum Cétuximab D03455 Erbitux Erbitux (TN) IMC-C225 Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer cetuximab |
| | 34 | | Cisplatin | approved | Phase 2, Phase 3, Phase 1 | 2770 | 15663-27-1 | 84093, 441203, 2767 | (SP-4-1)-diamminedichloridoplatinum (SP-4-1)-diamminedichloroplatinum (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum Abiplatin Biocisplatinum Briplatin CACP CDDP CHEBI:35852 CID441203 CPD0-1392 CPDC CPDD Carboquone Cis Pt II Cis-DDP Cis-Diaminedichloroplatinum Cis-Diamminedichloroplatinum Cismaplat Cisplatine Cisplatino Cisplatinum Cisplatyl Citoplationo DB00515 DDP DDPT Diamminedichloroplatinum | EU-0100918 Lederplatin Neoplatin Peyrone's chloride Peyrone's salt Plastin Platamine Platiblastin Platidiam Platinex Platinol Platinol-AQ Platinoxan Platinum Ammine Chloride Platinum Ammonium Chloride Platinum Diamine Dichloride Randa Trans-DDP Trans-Diaminedichloroplatinum Trans-Diamminedichloroplatinum Trans-Dichlorodiammine Platinum Trans-Platinumdiammine Dichloride cis-DDP cis-Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) cis-[PtCl2(NH3)2] cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum(II) nchembio773-comp1 trans-diamminedichloridoplatinum(II) | |
| | 35 | | Letrozole | approved, investigational | Phase 3, Phase 2, Phase 1 | 397 | 112809-51-5 | 3902 | 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole 112809-51-5 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile) 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile AB00514009 AC-1193 AC1L1GYT AKOS005145822 BIDD:GT0015 BIDD:PXR0130 BPBio1_001331 BRD-K88789588-001-03-2 BSPBio_001209 Bio-0057 C067431 C08163 C17H11N5 CAS-112809-51-5 CCRIS 8822 CGS 20267 CGS 20267, Femara, Piroxicam, Letrozole CGS-20267 CHEBI:6413 CHEMBL1444 CID3902 CPD000466343 | D00964 DB01006 FEM-345 Femara Femara (TN) Femera HMS1571M11 HMS2051E08 HMS2089L22 HSDB 7461 I06-0022 LS-38788 Letoval Letrozol Letrozole (JAN/USP/INN) Letrozole [USAN:INN] MLS000759455 MLS001424038 MLS002584991 MolPort-003-848-373 NCGC00016973-01 NCGC00016973-02 NSC719345 Novartis Brand of Letrozole Prestwick0_001025 Prestwick1_001025 Prestwick2_001025 Prestwick3_001025 S1235_Selleck SAM001246649 SMR000466343 SPBio_003070 TL8000371 UNII-7LKK855W8I ZINC03778874 letrozole |
| | 36 | | Gemcitabine | approved | Phase 3, Phase 2, Phase 1 | 2018 | 95058-81-4 | 60750 | 103882-84-4 122111-03-9 2',2'-DiF-dC 2',2'-Difluoro-2'-deoxycytidine 2',2'-Difluorodeoxycytidine 2'-Deoxy-.beta.-D-2',2'-difluorocytidine 2'-Deoxy-2',2'-difluorocytidine 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one 4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 95058-81-4 AB1004842 AC1L1TUQ C07650 CCRIS 8984 CHEBI:175901 CHEMBL888 CID60750 Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine D02368 DB00441 DDFC DFDC DFdC DFdCyd Folfugem GEO Gamcitabine GemLip Gemcel | Gemcin Gemcitabin Gemcitabina Gemcitabina [INN-Spanish] Gemcitabine Gemcitabine (USAN/INN) Gemcitabine HCl Gemcitabine hydrochloride Gemcitabine stereoisomer Gemcitabinum Gemcitabinum [INN-Latin] Gemtro Gemzar Gemzar (hydrochloride) HMS2089P10 HSDB 7567 Inno-D07001 LS-59139 LY 188011 LY-188011 LY188011 NCGC00168784-01 NChemBio.2007.10-comp25 NSC 613327 NSC613327 TL8005979 UNII-B76N6SBZ8R ZINC18279854 Zefei gemcitabine nchembio.573-comp7 nchembio.90-comp2 | |
| | 37 | | Sorafenib | approved, investigational | Phase 3, Phase 2, Phase 1 | 700 | 284461-73-0 | 216239, 406563 | 284461-73-0 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AB1004622 AC-1674 AC1L50CF BAX BAY 43-9006 BAY 43-9006 (free base) BAY 43-9006 tosylate salt BAY 439006 BAY 54-9085 (tosylate salt) BAY-43-0006 BAY-43-9006 BAY-54-9085 BAY43-9006 BRD-K23984367-001-01-8 Bio-0100 CHEBI:47228 CHEBI:50924 CHEMBL1336 CID216239 | D08524 DB00398 DB07438 EN002709 I06-0856 K00597a Kinome_766 LS-186067 LS-187021 LS-187788 MolPort-003-850-270 N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea NCGC00167488-01 NSC-724772 NSC747971 Nexavar STK627350 Sorafenib Sorafenib (INN) Sorafenib [INN] Sorafenib tosylate Sorafenibum UNII-9ZOQ3TZI87 ZINC01493878 nchembio.117-comp17 sorafenib sorafenibum | |
| | 38 | | Doxorubicin | approved, investigational | Phase 2, Phase 3, Phase 1 | 1751 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 39 | | Trametinib | approved | Phase 2, Phase 3, Phase 1 | 131 | 871700-17-3 | 11707110 | GSK 1120212 GSK1120212 JTP 74057 JTP-74057 | MEK Inhibitor GSK1120212 Mekinist Trametinib Dimethyl Sulfoxide Trametinibum trametinib | |
| | 40 | | Prednisolone | approved, vet_approved | Phase 2, Phase 3 | 1193 | 50-24-8 | 5755 | (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione .DELTA.1-Cortisol .DELTA.1-Dehydrocortisol .DELTA.1-Dehydrohydrocortisone .DELTA.1-Hydrocortisone .delta.-Cortef .delta.-Stab 1,2-Dehydrohydrocortisone 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol 1-Dehydrocortisol 1-Dehydrohydrocortisone 3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene 46656_FLUKA 46656_RIEDEL 50-24-8 58201-11-9 8056-11-9 AC-1773 AC1L1L2E Ak-Pred Ak-Tate Alphadrol Articulose-50 BPBio1_000164 BRD-K98039984-001-03-0 BRN 1354103 BSPBio_000148 Bio-0666 Bubbli-Pred C07369 CCRIS 980 CHEBI:8378 CHEMBL131 CID5755 CO-Hydeltra CPD000718761 Co-Hydeltra Codelcortone Cordrol Cortalone Cotogesic Cotolone D00472 D011239 DB00860 Decaprednil Decortin H Delcortol Delta F Delta(1)-dehydrohydrocortisone Delta-Cortef Delta-Cortef (TN) Delta-Ef-Cortelan Delta-Stab Delta-stab Deltacortenol Deltacortril Deltacortril Enteric Deltahydrocortisone Deltasolone Deltisilone Depo-Medrol Derpo PD Derpo Pd Dexa-Cortidelt Hostacortin H Dexa-Cortidelt hostacortin H Di Adreson F Di-Adreson F Di-Adreson-F Di-adreson F DiAdresonF Dicortol Donisolone Dydeltrone EINECS 200-021-7 Eazolin D Econopred Econopred Plus Erbacort Erbasona Estilsona Fernisolone Fernisolone P Fernisolone-P Flamasone HMS1568H10 HMS2090J05 HSDB 3385 Hostacortin H Hydeltra Hydeltra-Tba Hydeltrasol Hydeltrone Hydrodeltalone Hydrodeltisone Hydroretrocortin Hydroretrocortine I-Pred Inflamase Forte Inflamase Mild K 1557 Key-Pred Klismacort LMST02030179 LS-7669 Lentosone Lite Pred M-Predrol | MLS001304083 MLS002154250 MLS002207037 Medrol Medrol Acetate Metacortandralone Methylprednisolone Acetate Meti-Derm Meticortelone Metreton MolPort-002-507-147 NCGC00179649-01 NSC 9120 NSC9120 NSC9900 Neo-Delta-Cortef Nisolone Nor-Pred T.B.A. Ocu-Pred Ocu-Pred Forte Ophtho-Tate Orapred P0152_SIGMA P0637 P6004_SIGMA PRDL PRED-G Panafcortelone Paracortol Paracotol Pediapred Poly-Pred Precortalon Precortancyl Precortilon Precortisyl Pred Forte Pred Mild Predair Predair A Predair Forte Predalone 50 Predalone T.B.A. Predate Predate Tba Predate-50 Predcor-25 Predcor-50 Predcor-Tba Predisolone Sodium Phosphate Predne-Dome Prednelan Predni-Dome Prednicen Predniliderm Predniretard Prednis Prednisolona Prednisolona [INN-Spanish] Prednisolone (JP15/USP/INN) Prednisolone (anhydrous) Prednisolone Acetate Prednisolone Sodium Phosphate Prednisolone Tebutate Prednisolone [INN:BAN:JAN] Prednisolonum Prednisolonum [INN-Latin] Predonin Predonine Prelone Prenolone Prestwick0_000274 Prestwick1_000274 Prestwick2_000274 Prestwick3_000274 Prestwick_404 Rolisone S1737_Selleck SAM002264639 SMR000718761 SPBio_002367 Scherisolon Solone Steran Sterane Sterolone Supercortisol UNII-9PHQ9Y1OLM Ulacort Ultra Pred Ultracorten H Ultracortene H Ultracortene-H Ultracortene-Hydrogen Ultracortene-hydrogen ZINC03833821 component of Ataraxoid component of K-Predne-Dome delta(1)-Cortisol delta(1)-Dehydrocortisol delta(1)-Dehydrohydrocortisone delta(1)-Hydrocortisone delta(sup 1)-Cortisol delta(sup 1)-Dehydrocortisol delta(sup 1)-Dehydrohydrocortisone delta(sup 1)-Hydrocortisone delta-dehydrocortisol delta-dehydrohydrocortisone delta-hydrocortisone prednisolone | |
| | 41 | | Topotecan | approved, investigational | Phase 2, Phase 3 | 349 | 119413-54-6, 123948-87-8 | 60700 | (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione 123948-87-8 9-Dimethylaminomethyl-10-hydroxycamptothecin 9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin AC-11592 AC1L1TQZ AC1Q6APZ BSPBio_002348 C11158 C23H23N3O5 CCRIS 8163 CHEBI:107501 CHEBI:46035 CHEMBL84 CID60700 D08618 DB01030 HMS2090B20 HSCI1_000228 Hycamptamine Hycamptin Hycamtamine Hycamtin Hycamtin (TN) LS-127395 | MLS000759456 NCGC00178695-01 NCI60_004771 NCIStruc1_001659 NCIStruc2_001796 NChemBio.2007.10-comp24 NSC609699 SK&F-104864-A SKF 104864 SKF-104864-A SKF-S 104864 SMP2_000312 SMP2_000327 SMR000466344 TOPO TOPOTECAN, HYCAMTIN TPT TTC Topotecan (BAN) Topotecan Hcl Topotecan Hydrochloride Topotecan Lactone Topotecan Monohydrochloride, (S)-Isomer Topotecan [INN:BAN] Topotecan lactone Topotecane Topotecane [INN-French] Topotecanum Topotecanum [INN-Latin] UNII-7M7YKX2N15 topotecan |
| | 42 | | Leuprolide | approved, investigational | Phase 2, Phase 3 | 299 | 53714-56-0 | 3911, 657181 | (D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone 5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide AC1L1GZK AC1L9B44 AC1Q5OPO AR-1G9354 C07612 CID3911 CID441410 D00989 D08113 Enantone Enantone (TN) I04-0109 L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide L001094 | L002030 Leuprolide Leuprolide acetate Leuprolide acetate (USAN) Leuprorelin Leuprorelin (INN) Leuprorelin acetate (JAN) Leuprorelina Leuproreline Leuprorelinum Lupron (TN) N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide NSC377526 NSC746847 PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5 PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet acetic acid leuprolide | |
| | 43 | | Exemestane | approved, investigational | Phase 3, Phase 2, Phase 1 | 218 | 107868-30-4 | 60198 | (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione 107868-30-4 6-Methylenandrosta-1,4-diene-3,17-dione 6-Methyleneandrosta-1,4-diene-3,17-dione 6-methylideneandrosta-1,4-diene-3,17-dione AC-2171 AC1L1SRB AC1Q6AAZ Ambap107868-30-4 Aromasil Aromasin Aromasin (TN) Aromasin, Exemestane Aromasine C056516 C08162 CHEBI:4953 CHEMBL1200374 CID60198 CPD000466314 Curator_000009 D00963 DB00990 EXE EXEMESTANE | Exemestance Exemestane Exemestane (JAN/USP/INN) Exemestane [USAN:INN:BAN] Exemestano Exemestano [INN-Spanish] Exemestanum Exemestanum [INN-Latin] FCE-24304 Fce 24304 HMS2051J04 HSDB 7463 LS-19329 MLS000759419 MLS001424062 MolPort-003-847-343 NSC713563 Nikidess PNU-155971 Pfizer brand of exemestane S1196_Selleck S1196_Sellek SAM001246574 SMR000466314 UNII-NY22HMQ4BX ZINC03973334 exemestane |
| | 44 | | Goserelin | approved | Phase 2, Phase 3 | 233 | 65807-02-5 | 47725, 5311128 | (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide AC1NSK1T CID5311128 Goserelin Goserelin acetate | HMS2089D16 HS-2015 ICI-118630 MolPort-006-823-831 ZD-9393 Zoladex goserelin |
| | 45 | | Pertuzumab | approved | Phase 3, Phase 2, Phase 1 | 127 | 145040-37-5, 380610-27-5 | 2540 | 2C4 Antibody 380610-27-5 D05446 Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer LS-185920 MOAB 2C4 MOAB2C4 Monoclonal Antibody 2C4 | Omnitarg Perjeta Pertuzumab Pertuzumab (USAN/INN) Pertuzumab (genetical recombination) Pertuzumab (genetical recombination) (JAN) pertuzumab rhuMAb 2C4 rhuMAb-2C4 | |
| | 46 | | Methotrexate | approved | Phase 3, Phase 1, Phase 2 | 1551 | 1959-05-2, 59-05-2 | 126941 | 4-amino-10-methylfolic acid 4-amino-N(10)-methylpteroylglutamic acid Abitrexate Amethopterin Amethopterine Antifolan Arbitrexate Emtexate Folex HDMTX L-Amethopterin Ledertrexate MTX Metatrexan | Methopterin Methotextrate Methotrate Methotrexat Methotrexate Sodium Methotrexatum Methylaminopterin Methylaminopterinum Metotrexato Mexate Méthotrexate N-Bismethylpteroylglutamic Acid N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid Rheumatrex Trexall | |
| | 47 | | Lidocaine | approved, vet_approved | Phase 3 | 1317 | 137-58-6 | 3676 | .alpha.-(Diethylamino)-2,6-acetoxylidide .alpha.-Diethylamino-2,6-dimethylacetanilide .alpha.-Diethylaminoaceto-2,6-xylidide .omega.-Diethylamino-2,6-dimethylacetanilide 137-58-6 2-(Diethylamino)-2',6'-acetoxylidide 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide 4-12-00-02538 (Beilstein Handbook Reference) 6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE)) 6108-05-0 (mono-hydrochloride, mono-hydrate) 73-78-9 (mono-hydrochloride) AB00053581 AC-10282 AC1L1GGQ AC1Q2Z7J AKOS001026768 ARONIS23855 After Burn Double Strength Gel After Burn Double Strength Spray After Burn Gel After Burn Spray Alphacaine Anestacon Anestacon Jelly BIDD:GT0342 BPBio1_000197 BRD-K52662033-001-02-6 BRD-K52662033-003-05-5 BRN 2215784 BSPBio_000179 BSPBio_001359 BSPBio_003004 Bio-0767 Bio1_000379 Bio1_000868 Bio1_001357 Bio2_000079 Bio2_000559 C07073 C14H22N2O CAS-73-78-9 CDS1_000283 CHEBI:6456 CHEMBL79 CID3676 CPD000058189 Cappicaine Cito optadren Cuivasil D00358 DB00281 Dalcaine Dentipatch Dentipatch (TN) DermaFlex Diethylaminoaceto-2,6-xylidide Dilocaine DivK1c_000174 DivK1c_001323 Duncaine EINECS 205-302-8 ELA-Max EMBOLEX Emla Emla Cream Esracaine FT-0082378 Gravocain HMS1791D21 HMS1989D21 HMS2051C21 HMS2089E15 HMS548M19 HSDB 3350 I01-2704 IDI1_000174 IDI1_033829 Isicaina Isicaine Jetocaine KBio1_000174 KBio2_000079 KBio2_001598 KBio2_002647 KBio2_004166 KBio2_005215 KBio2_006734 KBio3_000157 KBio3_000158 KBio3_002224 KBioGR_000079 KBioGR_000599 KBioSS_000079 KBioSS_001598 L-Caine L0156 L1026_SIGMA L7757_SIGMA LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE) LIDOPEN LQZ | LS-805 Lanabiotic Leostesin Lida-Mantle Lidocaina Lidocaina [INN-Spanish] Lidocaine (JP15/USP/INN) Lidocaine (VAN) Lidocaine Carbonate Lidocaine Hydrocarbonate Lidocaine Monohydrochloride Lidocaine [USAN:INN:JAN] Lidocainum Lidocainum [INN-Latin] Lidocaton Lidoderm Lidoject-1 Lidoject-2 Lignocaine Lignocainum Lingocaine Lopac-L-5647 Lopac0_000669 MLS000069724 MLS000758263 MLS001074177 Maricaine Maybridge1_002571 MolPort-001-783-478 N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide NCGC00015611-01 NCGC00015611-02 NCGC00015611-03 NCGC00015611-04 NCGC00015611-14 NCGC00022176-05 NCGC00022176-06 NCGC00022176-07 NCGC00022176-08 NCGC00022176-09 NINDS_000174 NSC 40030 NSC40030 Norwood Sunburn Spray Octocaine Octocaine-100 Octocaine-50 Prestwick0_000050 Prestwick1_000050 Prestwick2_000050 Prestwick3_000050 Remicaine Rocephin Kit Rucaina S1357_Selleck SAM001247018 SMR000058189 SPBio_001525 SPBio_002100 STK552033 Solarcaine Solarcaine aloe extra burn relief cream Solcain Spectrum2_001343 Spectrum3_001392 Spectrum4_000070 Spectrum5_001549 Spectrum_001118 UNII-98PI200987 WLN: 2N2 & 1VMR B1 F1 Xilina Xilocaina Xilocaina [Italian] Xllina Xycaine Xylestesin Xylesthesin Xylocain Xylocaine Xylocaine (TN) Xylocaine 5% Spinal Xylocaine CO2 Xylocaine Dental Ointment Xylocaine Endotracheal Xylocaine Test Dose Xylocaine Viscous Xylocaine-MPF Xylocaine-MPF with Glucose Xylocaine-Mpf Xylocaine-Mpf with Glucose Xylocard Xylocitin Xyloneural (free base) Xylotox Zilactin-L Zingo alfa-Dietilamino-2,6-dimetilacetanilide alfa-Dietilamino-2,6-dimetilacetanilide [Italian] alpha-Diethylamino-2,6-dimethylacetanilide alpha-diethylamino-2,6-dimethylacetanilide lidocaine nchembio.65-comp16 α-diethylamino-2,6-dimethylacetanilide | |
| | 48 | | Methylprednisolone | approved, vet_approved | Phase 2, Phase 3 | 1193 | 83-43-2 | 6741 | (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione .DELTA.1-6.alpha.-Methylhydrocortisone 1-Dehydro-6alpha-methylhydrocortisone 1-dehydro-6alpha-Methylhydrocortisone 1-dehydro-6α-methylhydrocortisone 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 121673-01-6 4-08-00-03498 (Beilstein Handbook Reference) 46436_FLUKA 46436_RIEDEL 570-35-4 6 Methylprednisolone 6-Methylprednisolone 6-alpha-Methylprednisolone 6.alpha.-Methylprednisolone 6923-42-8 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 6alpha-Methylprednisolone 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 83-43-2 AC1L1N7A Artisone-Wyeth Artisone-wyeth BPBio1_000174 BRD-K35240538-001-03-1 BRN 2340300 BSPBio_000158 Besonia Bio-0658 CHEBI:6888 CHEMBL650 CID6741 CPD000058330 D00407 D008775 DB00959 Depo-Medrol (acetate) Dopomedrol EINECS 201-476-4 Esametone Firmacort HMS1568H20 HMS2090B13 HSDB 3127 LMST02030178 LS-118498 Lemod M0639_SIGMA M1665 MEPRDL MLS000028541 MLS001148159 MLS002207191 Medesone Medixon Medlone 21 | Medrate Medrol Medrol (TN) Medrol Adt Pak Medrol Dosepak Medrol adt pak Medrol dosepak Medrol, Solu-Medrol, Medrone, Methylprednisolone Medrone Mesopren Metastab Methyleneprednisolone Methylprednisolon Methylprednisolone Methylprednisolone (JP15/USP/INN) Methylprednisolone [USAN:INN:BAN:JAN] Methylprednisolone, 6-alpha Methylprednisolonum Methylprednisolonum [INN-Latin] Metilbetasone Metilprednisolona Metilprednisolona [INN-Spanish] Metilprednisolone Metilprednisolone [DCIT] Metilprednisolone [Dcit] Metipred Metrisone Metrocort Metysolon Moderin MolPort-002-528-554 NCGC00022735-03 NCI60_001657 NSC-19987 NSC19987 Nirypan Noretona Predni N Tablinen Prednol- L Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI) Prestwick0_000279 Prestwick1_000279 Prestwick2_000279 Prestwick3_000279 Prestwick_622 Promacortine Reactenol S1733_Selleck SAM002589984 SMR000058330 SPBio_002377 Sieropresol Solomet Summicort Suprametil U 7532 UNII-X4W7ZR7023 Urbason Urbasone Wyacort ZINC03875560 delta(1)-6alpha-Methylhydrocortisone delta(sup 1)-6-alpha-Methylhydrocortisone methylprednisolone methylprenisolone |
| | 49 | | Celecoxib | approved, investigational | Phase 2, Phase 3 | 444 | 169590-42-5 | 2662 | 169590-42-5 184007-95-2 1oq5 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide AC-4228 AC1L1E6K AI-525 BIDD:GT0408 BRD-K02637541-001-02-4 BSPBio_003596 Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) C07589 C105934 C17H14F3N3O2S CCRIS 8679 CEL CEP-33222 CHEBI:41423 CHEMBL118 CID2662 CPD000550473 Celebra Celebrex Celebrex (TN) Celebrex, Celebra, Celecoxib Celecox Celecoxi Celecoxib Celecoxib (JAN/USAN/INN) Celecoxib (SC-58635) Celecoxib [Old RN] Celecoxib [USAN] Celecoxibum Celocoxib Célécoxib D00567 DB00482 DivK1c_000893 Eurocox FT-0080064 HMS1922G14 HMS2089L18 HMS2093I07 HMS502M15 HSDB 7038 I01-1033 IDI1_000893 KBio1_000893 KBio2_000912 | KBio2_002351 KBio2_003480 KBio2_004919 KBio2_006048 KBio2_007487 KBio3_002830 KBio3_003037 KBioGR_000723 KBioGR_002351 KBioSS_000912 KBioSS_002354 LS-31667 MLS001165684 MLS001195656 MLS001304708 Medicoxib MolPort-002-885-815 NCGC00091455-01 NCGC00091455-02 NCGC00091455-03 NCGC00091455-04 NCI60_041049 NINDS_000893 NSC719627 Onsenal P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide Pfizer brand of celecoxib S1261_Selleck SAM002589995 SC 58635 SC-58553, SC-58635 SC-58635 SC58635 SMR000550473 SPBio_001512 SPECTRUM1503678 Solexa Spectrum2_001576 Spectrum3_001996 Spectrum4_000182 Spectrum5_001324 Spectrum_000432 TL8001323 TPI-336 UNM-0000305813 Xilebao YM 177 YM-177 YM177 ZINC02570895 cMAP_000027 celecoxib p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide | |
| | 50 | | Oxybutynin | approved, investigational | Phase 3 | 68 | 5633-20-5 | 4634 | 1508-65-2 (hydrochloride) 4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate 4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate 5633-20-5 AC-2153 AC1L1ILV BPBio1_000214 BRD-A65013509-003-03-8 BSPBio_000194 Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester C07360 CCRIS 1923 CHEBI:7856 CHEMBL1231 CID4634 Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester Cystrin D00465 DB01062 Ditropan Ditropan, Lyrinel XL, Oxytrol, Oxybutynin FT-0082890 HSDB 3270 I06-2117 L000923 LS-28714 | Lopac0_000923 MolPort-003-849-741 NCGC00015767-06 NCGC00089795-02 Oxibutinina Oxibutinina [INN-Spanish] Oxibutyninum Oxybutinin Oxybutynin Oxybutynin (USAN/INN) Oxybutynin Base Oxybutynin Chloride Oxybutynin Hydrochloride Oxybutynin [USAN:INN:BAN] Oxybutynin topical gel Oxybutynine Oxybutynine [INN-French] Oxybutyninum Oxybutyninum [INN-Latin] Oxytrol Oxytrol (TN) Pollakisu Prestwick0_000287 Prestwick1_000287 Prestwick2_000287 Prestwick3_000287 S1754_Selleck SPBio_002413 Transdermal patch UNII-K9P6MC7092 oxybutynin oxybutynin topical gel transdermal patch | |
|
Interventional clinical trials: (show top 50)
(show all 499)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET | Completed | NCT00904410 | Phase 4 | | 2 | Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy | Completed | NCT00616135 | Phase 4 | | 3 | Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer | Completed | NCT00742222 | Phase 4 | | 4 | Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® | Completed | NCT01448447 | Phase 4 | | 5 | Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) | Unknown status | NCT01126138 | Phase 3 | | 6 | Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer | Completed | NCT00949598 | Phase 3 | | 7 | Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer | Completed | NCT00140075 | Phase 3 | | 8 | Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | Completed | NCT00096278 | Phase 3 | | 9 | Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy | Completed | NCT00053898 | Phase 3 | | 10 | Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis | Completed | NCT00243685 | Phase 2, Phase 3 | | 11 | Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer | Completed | NCT01508546 | Phase 3 | | 12 | Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer | Completed | NCT01112254 | Phase 3 | | 13 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer | Completed | NCT01426880 | Phase 2, Phase 3 | | 14 | Intraoperative Gamma Camera for Breast Cancer Surgery | Completed | NCT00757302 | Phase 3 | | 15 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | Completed | NCT00079274 | Phase 3 | | 16 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Completed | NCT00262847 | Phase 3 | | 17 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | Completed | NCT00538850 | Phase 3 | | 18 | S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy | Completed | NCT00134056 | Phase 3 | | 19 | An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation | Completed | NCT00132704 | Phase 3 | | 20 | GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma | Completed | NCT00495846 | Phase 2, Phase 3 | | 21 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | Completed | NCT00326898 | Phase 3 | | 22 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | Recruiting | NCT02488967 | Phase 3 | | 23 | Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer | Recruiting | NCT01916317 | Phase 3 | | 24 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery | Recruiting | NCT01013649 | Phase 3 | | 25 | Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 | Recruiting | NCT02620280 | Phase 3 | | 26 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients | Recruiting | NCT02221999 | Phase 2, Phase 3 | | 27 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | Recruiting | NCT02125344 | Phase 3 | | 28 | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy | Recruiting | NCT02879513 | Phase 3 | | 29 | STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial | Recruiting | NCT00268476 | Phase 2, Phase 3 | | 30 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Recruiting | NCT01272037 | Phase 3 | | 31 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | Recruiting | NCT01953588 | Phase 3 | | 32 | Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer | Recruiting | NCT01905046 | Phase 3 | | 33 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | Recruiting | NCT02101788 | Phase 2, Phase 3 | | 34 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting | NCT00565851 | Phase 3 | | 35 | Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery | Recruiting | NCT01101451 | Phase 3 | | 36 | Oxybutynin Chloride in Managing Hot Flashes | Recruiting | NCT02961790 | Phase 3 | | 37 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | Recruiting | NCT02065687 | Phase 2, Phase 3 | | 38 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | Recruiting | NCT01575548 | Phase 3 | | 39 | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC | Recruiting | NCT02627963 | Phase 3 | | 40 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | Active, not recruiting | NCT00005970 | Phase 3 | | 41 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Active, not recruiting | NCT00310180 | Phase 3 | | 42 | Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | Active, not recruiting | NCT00869206 | Phase 3 | | 43 | Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator | Active, not recruiting | NCT00321048 | Phase 3 | | 44 | Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | Active, not recruiting | NCT00556374 | Phase 3 | | 45 | A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | Active, not recruiting | NCT00887536 | Phase 3 | | 46 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | Active, not recruiting | NCT01196390 | Phase 3 | | 47 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) | Active, not recruiting | NCT01583426 | Phase 3 | | 48 | Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast | Active, not recruiting | NCT00470236 | Phase 3 | | 49 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | Active, not recruiting | NCT00769379 | Phase 3 | | 50 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Active, not recruiting | NCT00265850 | Phase 3 |
|
